Washington — The Senate health committee is set to question Dr. Heidi Overton, President Trump’s nominee to lead the Food and Drug Administration, on Thursday. Overton, a longtime White House aide and former executive at the America First Policy Institute, has built her career on advancing the administration’s health agenda, including efforts to overhaul childhood vaccines and restrict the abortion pill.
Conservative credentials under scrutiny
Overton’s résumé includes work on the revamped food pyramid, a push to break up combination vaccines, and support for new rules that would make flavored electronic cigarettes easier to sell. Those positions align with President Trump’s goal of slashing unnecessary regulations while protecting families from what the administration calls unsafe medical products.
Senate Health Committee Chairman Sen. Bill Cassidy (R‑LA), a physician, called Overton’s support for spacing out vaccinations “almost disqualifying,” but he also noted that her hard‑line stance on the abortion pill could find common ground with other Republican senators who have urged the FDA to limit access to mifepristone.
Abortion pill and vaccine controversy
Overton has repeatedly criticized the FDA’s 2023 decision—made under the previous administration—to allow mifepristone to be mailed to patients, labeling the practice as “chemical abortion on demand.” She also echoed the Trump administration’s claim that combination vaccines may be linked to autism, a view the FDA has long rejected as unsupported by scientific evidence.
While the FDA has affirmed the safety of mifepristone since its 2000 approval, Health Secretary Robert F. Kennedy ordered a safety reevaluation last year after pressure from anti‑abortion groups and Trump‑aligned lawmakers. FDA officials have said the review is ongoing but have provided few details.
Republican and moderate dynamics
Beyond the abortion issue, Overton’s nomination could test the Senate’s ability to bridge the gap between staunch conservatives and moderate Republicans such as Sen. Susan Collins (R‑ME) and Sen. Lisa Murkowski (R‑AK), both of whom have supported federal access to abortion services. Collins is currently in a tight reelection race where abortion access is a central campaign theme.
To become commissioner, Overton must first secure a majority vote from the 21‑member health committee before moving to the full Senate for confirmation.
Agency context under the Trump administration
Since President Trump took office, the FDA has faced a dual mandate: reduce regulatory burdens—especially on vaping products—while intensifying scrutiny of vaccines, drugs and food ingredients at the direction of the White House. The agency has seen a roughly 20% reduction in staff through layoffs, buyouts, retirements and resignations, a trend that began under the previous commissioner, Dr. Marty Makary.
Overton studied under Makary at Johns Hopkins University, earning a doctorate in clinical research after completing her medical degree at the University of New Mexico. Like her predecessor, she has no prior experience running a large bureaucracy, a factor that some Senate members say will be a test of her leadership abilities.
Financial disclosures
In required financial disclosure forms, Overton reported no investments in health‑care or food companies, contrasting with past FDA nominees who have had to divest holdings. She disclosed student loans ranging from $50,000 to $100,000.
The nomination comes at a time when the Trump administration continues to prioritize policies that protect traditional families, uphold individual liberty and reflect Christian values, all while seeking to ensure that federal agencies serve the public rather than special interests.
Original reporting: Alexandria, VA News – WTOP News — read the source article.
